A Randomized, Double Blinded, Placebo Controlled, Parallel-Group Study to Evaluate the Safety and Efficacy of CurQlife 500 mg and CurQlife P 500 mg in Reducing Symptoms of Knee Osteoarthritis

Start Date15 Jan 2014

Sponsor / Collaborator

Laila Pharmaceuticals Pvt. Ltd

[+1]

CTRI/2013/08/003891

/ CompletedPhase 2

A Randomized, Double-Blind, Placebo-Control Study to Evaluate Efficacy and Safety of a novel formulation on Weight Management in Healthy Volunteers

Start Date12 Aug 2013

Sponsor / Collaborator

Iovate Health Sciences International, Inc.

[+1]

CTRI/2013/05/003663

/ CompletedPhase 3

A Randomized, Double-Blind, Placebo-Controlled Trial to Assess the Efficacy and Tolerability of UC-IIÂ® in modulating knee joint function

Start Date01 Jun 2013

Sponsor / Collaborator

InterHealth Nutraceuticals, Inc.

[+1]

100 Clinical Results associated with Laila Pharmaceuticals Pvt. Ltd

0 Patents (Medical) associated with Laila Pharmaceuticals Pvt. Ltd

Literatures (Medical) associated with Laila Pharmaceuticals Pvt. Ltd

01 Jan 2012·American Journal of Infectious Diseases

Molecular Medicine-Prospects and Challenges

Author: Sripathy, R. ; Somashekara, N. ; Upadhyay, R. ; Vyas, A. ; Buch, A. ; Ramchand, C. N. ; Pant, H.

A review.Drug discovery and development is a process that rationally leads to instigation of compound or formulation for the treatment of particular disease/diseased condition by acting on its specific target (s).Most of the drugs identified by conventional drug discovery process were as a result of unsystematic, random and serendipitous approach.Enhancement of knowledge in the field of biotechnol., mol. biol. and medicinal chem. improved the basic understanding of disease mechanism, mechanism of drug action resulting in a paradigm shift in drug discovery approach towards development of targeted drug discovery.Currently, mol. medicine encompassing elucidation of the genetic basis of disease, diagnosis of the disease and the design of an appropriate approach to disease management or therapy, promises to be an effective strategy for modern drug discovery.The change in approach resulted in improvement in target innovation, however doesn't impact the rate of NMEs approved.The challenges limiting the drug discovery and prospects offered by mol. medicine and reverse pharmacol. for its improvement were discussed in this review.

01 Jan 2012·American Journal of Infectious Diseases

In Silico, In Vitro and In Vivo Assessment of Safety and Anti-inflammatory Activity of Curcumin

Author: Sripathy, R. ; Verma, S. Rama ; Anjana, D. ; Somashekara, N. ; Murali, M. ; Krishnaraju, A. ; Krishanu, S. ; Venkata, M. ; Ramchand, C. N.

Problem statement: Curcumin the active component of turmeric is known for its wide biol. actions.Extensive studies on curcumin highlighted its anti-inflammatory, anti-oxidant, antimicrobial, anti-carcinogenic and anti-coagulant activity.The anti-inflammatory activities of curcumin have been demonstrated both in vitro and in vivo.Though curcumin and its anti-inflammatory properties are well documented, the exact mechanism of action and effective in vivo dosage required for potential anti-inflammatory activity of curcumin are yet to be determinedThe current work reflects in identifying the the role curcumin in the inflammatory cascade and arriving at an optimal ED (ED₅₀).Approach: The objective of the current study is to understand and establish the role of curcumin in the treatment of inflammatory condition, through in-silico, in-vitro and in-vivo studies.The specificity and binding affinity of curcumin to major inflammatory mediators such as, cytokines/chemokines, signaling proteins and transcription factors were evaluated using mol. docking.Subsequently, in-vitro experiments were conducted to establish the role of curcumin in reducing the release of histamine and β-hexosaminidase form U937 human monocytes cell lines.Further, the ED (ED₅₀) of curcumin was established for its potent in vivo anti-inflammatory activity.Results: Our study confirmed a strong affinity of curcumin to various inflammatory mediators (ERK, PKC, P38 MAP Kinase, NFkB and Lipoxygenase).Curcumin when studied for its affinity towards chemokines/cytokines and TNF-α was found to be ineffective.Proportionate reduction in histamine and β-hexosaminidase release in U937 cells in vitro and inhibition of paw edema in carrageenan induced inflammation in rats affirmed the dose dependent anti-inflammatory activity of curcumin.This in vivo study elucidated the ED₅₀ value to be 570.6 mg kg^-1 body weight for curcumin, which apparently shall be the potent dose to screen its anti-inflammatory activity.Conclusion: Overall results suggest that, curcumin mediates its anti-inflammatory activity by its direct effect on multi-target inflammatory mediators while others were mediated by the downstream effects of curcumin.Curcumin can be a potent mol. in treatment of various diseases associated with inflammation, with its multi-target potency and high safety profile.

01 Jan 2012·American Journal of Infectious Diseases

Development of Curcumin Based Ophthalmic Formulation

Author: Verma, S. Rama ; Somashekara, N. ; Venkata, M. ; Sripathy, R. ; Anjana, D. ; Nair, Anitha ; Yelucheri, Rajesh ; Ramchand, C. N. ; Parmar, H. ; Upadhyay, R.

Problem statement: Ophthalmic drug delivery system has been a major challenge due to the distinctive and unique anatomy of the eye.The use of phytochems. for the application in ocular disease has not been investigated much, due to poor pharmacokinetics of phytochem. and hence poor therapeutic efficacy.Approach: Curcumin is one such phytochem. known for its medicinal properties, but its usage has been limited due to its poor bioavailability.Therapeutic ocular application of curcumin for indications such as allergic conjunctivitis and use of nanotechnol. based delivery system for increasing its bioavailability haven't been explored much.Thus the objective of current study was to develop a nanoemulsification based formulation for curcumin with enhanced bioavailability and efficacy for ophthalmic therapeutic application.Different surfactants and oils were screened based on its ability to solubilize hydrophobic curcumin for developing formulation.Ultrasonication was used for dispersion of curcumin in surfactants and nanoemulsification.Characterization of the selected formulation was done based on particle size, Transmission Electron Microscope (TEM) and Scanning Electron Microscope (SEM) anal. and tested for different physiochem. properties.Results: A novel formulation was developed through nanoemulsification technol. by ultrasonication using carefully selected nonionic surfactants.Acconon and Tween 80 were chosen after thorough screening studies.The ratio of curcumin: Acconon: Tween80: water (0.12:1:7:1) was found to be optimum for the formulation.Particle size anal. showed that the nano droplets are in the range of 8-22 nm.Further the TEM and SEM studies also confirmed that the nanodroplets are in spherical shape.Formulation was found to be stable as ascertained by phase separation and observational studies.Conclusion: The studies ensured the stability and formation of characteristic nanodroplets with curcumin entrapment as a result of the developed formulation.The so developed formulation is expected to have higher ophthalmic bioavailability, which further needs to be confirmed through in vitro and in vivo studies.

100 Deals associated with Laila Pharmaceuticals Pvt. Ltd

100 Translational Medicine associated with Laila Pharmaceuticals Pvt. Ltd

Corporation Tree

Boost your research with our corporation tree data.

view full example data

Pipeline

Pipeline Snapshot as of 10 May 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Other

Current Projects

Drug(Targets)	Indications	Global Highest Phase

LP-001-09	Psoriasis More	Discontinued
LP-002-09	Conjunctivitis, Allergic More	Discontinued
LP-004-09	Stomatitis More	Discontinued
LP-013-09	Cataract More	Discontinued
LPO-1010AM	Dystrophy, Macular More	Pending

Deal

Boost your decision using our deal data.

view full example data

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Profit

Explore the financial positions of over 360K organizations with Synapse.

view full example data

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.

view full example data

Investment

Gain insights on the latest company investments from start-ups to established corporations.

view full example data

Financing

Unearth financing trends to validate and advance investment opportunities.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Laila Pharmaceuticals Pvt. Ltd

Overview

Related

Corporation Tree

Pipeline

Pipeline Snapshot as of 10 May 2025

Current Projects

Deal

Translational Medicine

Profit

Grant & Funding(NIH)

Investment

Financing